Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes

Annals of Oncology

Volumn 27, Issue 4, 2016, Pages 635-641

  San Lucas, F A ^a   Allenson, K ^a   Bernard, V ^a,b   Castillo, J ^a   Kim, D U ^a   Ellis, K ^a   Ehli, E A ^c   Davies, G E ^c   Petersen, J L ^c   Li, D ^a   Wolff, R ^a   Katz, M ^a   Varadhachary, G ^a   Wistuba, I ^a   Maitra, A ^a   Alvarez, H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c Avera Institute for Human Genetics   (United States)

Author keywords

Exosomes; Liquid biopsy; Next generation sequencing; Pancreatic cancer

Indexed keywords

BRCA2 PROTEIN; NOTCH1 RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRCA2 GENE; CASE REPORT; COPY NUMBER VARIATION; EXOSOME; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE FUSION; GENE IDENTIFICATION; GENE SEQUENCE; HUMAN; LIVER METASTASIS; MALE; MINIMALLY INVASIVE PROCEDURE; NEXT GENERATION SEQUENCING; NOTCH1 GENE; PANCREAS ADENOCARCINOMA; POINT MUTATION; PRIORITY JOURNAL; RNA SEQUENCE; BIOSYNTHESIS; EXOME; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; PANCREAS TUMOR; PATHOLOGY;

AGED; BIOMARKERS, TUMOR; EXOME; EXOSOMES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS;

EID: 84964680481     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv604     Document Type: Article

References (27)

1. Chantrill LA, Nagrial AM, Watson C et al. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. Clin Cancer Res 2015; 354: 1698-1705.
2. Taly V, Pekin D, Benhaim L et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 2013; 59: 1722-1731.
3. Lanman RB, Mortimer SA, Zill OA et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. PLoS One 2015; 10: e0140712.
4. Zill OA, Greene C, Sebisanovic D et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov 2015; 5: 1040-1048.
5. Chan KC, Jiang P, Zheng YW et al. Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 2013; 59: 211-224.
6. Murtaza M, Dawson SJ, Tsui DW et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112.
7. Butler TM, Johnson-Camacho K, Peto M et al. Exome sequencing of cell-free DNA from metastatic cancer patients identifies clinically actionable mutations distinct from primary disease. PLoS One 2015; 10: e0136407.
8. Mouliere F, Robert B, Arnau Peyrotte E et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011; 6: e23418.
9. Fleischhacker M. Biology of circulating mRNA: still more questions than answers? Ann N Y Acad Sci 2006; 1075: 40-49.
10. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
11. El-Hefnawy T, Raja S, Kelly L et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics. Clin Chem 2004; 50: 564-573.
12. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
13. Skog J, Wurdinger T, van Rijn S et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
14. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013; 91: 431-437.
15. Kahlert C, Melo SA, Protopopov A et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 2014; 289: 3869-3875.
16. Thakur BK, Zhang H, Becker A et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 2014; 24: 766-769.
17. Forbes SA, Beare D, Gunasekaran P et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res 2015; 43: D805-D811.
18. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
19. Consortium G. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015; 348: 648-660.
20. Overwijk WW, Wang E, Marincola FM et al. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer 2013; 1: 11.
21. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.
22. Waddell N, Pajic M, Patch AM et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
23. Balia C, Galli A, Caligo MA. Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells. Breast Cancer Res Treat 2011; 129: 1001-1009.
24. Lowery MA, Kelsen DP, Stadler ZK et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011; 16: 1397-1402.
25. Henjes F, Bender C, von der Heyde S et al. Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2- targeting drugs. Oncogenesis 2012; 1: e16.
26. Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutationspecific CD4+ T cells in a patient with epithelial cancer. Science 2014; 344: 641-645.
27. Gerlinger M, Horswell S, Larkin J et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-233.